Teva Pharmaceutical Industries (TEVA) Cash from Investing Activities: 2009-2025
Historic Cash from Investing Activities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $135.0 million.
- Teva Pharmaceutical Industries' Cash from Investing Activities fell 49.63% to $135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $774.0 million, marking a year-over-year decrease of 13.13%. This contributed to the annual value of $792.0 million for FY2024, which is 18.18% down from last year.
- As of Q3 2025, Teva Pharmaceutical Industries' Cash from Investing Activities stood at $135.0 million, which was down 42.80% from $236.0 million recorded in Q2 2025.
- Teva Pharmaceutical Industries' Cash from Investing Activities' 5-year high stood at $508.0 million during Q1 2021, with a 5-year trough of $135.0 million in Q3 2025.
- In the last 3 years, Teva Pharmaceutical Industries' Cash from Investing Activities had a median value of $201.0 million in 2025 and averaged $212.0 million.
- In the last 5 years, Teva Pharmaceutical Industries' Cash from Investing Activities skyrocketed by 101.59% in 2021 and then slumped by 68.31% in 2022.
- Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Cash from Investing Activities stood at $246.0 million in 2021, then crashed by 31.71% to $168.0 million in 2022, then soared by 79.17% to $301.0 million in 2023, then slumped by 32.89% to $202.0 million in 2024, then crashed by 49.63% to $135.0 million in 2025.
- Its Cash from Investing Activities was $135.0 million in Q3 2025, compared to $236.0 million in Q2 2025 and $201.0 million in Q1 2025.